Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया13% संभावना
$11,264 वॉल्यूम
$11,264 वॉल्यूम
7 अक्टू, 2026
13% संभावना
$11,264 वॉल्यूम
$11,264 वॉल्यूम
7 अक्टू, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
बाज़ार खुला: May 5, 2026, 8:02 PM ET
वॉल्यूम
$11,264समाप्ति तिथि
7 अक्टू, 2026बाज़ार खुला
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
वॉल्यूम
$11,264समाप्ति तिथि
7 अक्टू, 2026बाज़ार खुला
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for long-acting peptide formulations has not progressed to a commercial licensing agreement, supporting the 87.5% market-implied odds against a deal by the October 7 resolution date. The October 2024 collaboration remains limited to a 14-month non-exclusive research pact focused on internal R&D assessment rather than technology transfer or binding commercial terms. Recent updates show continued joint research committee activity through mid-2026 alongside Lilly’s parallel partnerships, such as its Camurus obesity-drug delivery deal, without any disclosed advancement or negotiation milestones for SmartDepot. The short remaining window, typical multi-month timelines for pharma licensing due diligence, and Peptron’s focus on scaling its own manufacturing capacity further reduce the likelihood of a surprise announcement. Traders are watching for any official statements or filings in the coming weeks that could shift sentiment before the deadline.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न